The development of BRAF and MEK inhibitors (respectively vemurafenib and trametinib, among others), shows great antitumorigenic effect in patients while also inducing senescence and contributing to radiosensitise BRAF‐mutated melanoma cells but also to explain the absence of complete response to vemurafenib [157, 158, 159]. This evidence concerns the gene BRAF and melanoma.